Welcome to our dedicated page for Harrow 8.625% Senior Notes due 2026 SEC filings (Ticker: HROWL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Harrow 8.625% Senior Notes due 2026's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Harrow 8.625% Senior Notes due 2026's regulatory disclosures and financial reporting.
Harrow, Inc. filed a Form 3 for Chief Commercial Officer Patrick William Sullivan, reporting a stock option over 30,000 shares of common stock. The option has an exercise price of $39 per share and expires on September 1, 2035.
According to the vesting schedule, 25% of the option shares vest on the one-year anniversary of the grant date. The remaining shares vest in 12 equal quarterly installments over the following three years, becoming fully vested and exercisable on September 1, 2029. The option is held directly.
Harrow, Inc. filed a Form 3 for Chief Commercial Officer Patrick William Sullivan, reporting a stock option over 30,000 shares of common stock. The option has an exercise price of $39 per share and expires on September 1, 2035.
According to the vesting schedule, 25% of the option shares vest on the one-year anniversary of the grant date. The remaining shares vest in 12 equal quarterly installments over the following three years, becoming fully vested and exercisable on September 1, 2029. The option is held directly.
Harrow, Inc. filed an update covering its outlook and leadership team. The company reaffirmed its full-year 2025 revenue guidance in a range of $270 million to $280 million, signaling no change to its previously communicated expectations.
Harrow also appointed Patrick W. Sullivan as Chief Commercial Officer, effective January 30, 2026. He brings more than 25 years of commercial leadership experience from roles at Corium Therapeutics, AstraZeneca, Shire, Adolor, Novartis, and Bayer. Under his offer letter, Sullivan will receive a $425,000 annual base salary, a target annual bonus equal to 40% of base compensation, and 40,000 restricted stock units. Of these, 25,000 RSUs vest if Harrow’s revenue reaches $230,000,000 in a calendar quarterly period, and 15,000 RSUs vest three years from the award date.
Harrow, Inc. filed an update covering its outlook and leadership team. The company reaffirmed its full-year 2025 revenue guidance in a range of $270 million to $280 million, signaling no change to its previously communicated expectations.
Harrow also appointed Patrick W. Sullivan as Chief Commercial Officer, effective January 30, 2026. He brings more than 25 years of commercial leadership experience from roles at Corium Therapeutics, AstraZeneca, Shire, Adolor, Novartis, and Bayer. Under his offer letter, Sullivan will receive a $425,000 annual base salary, a target annual bonus equal to 40% of base compensation, and 40,000 restricted stock units. Of these, 25,000 RSUs vest if Harrow’s revenue reaches $230,000,000 in a calendar quarterly period, and 15,000 RSUs vest three years from the award date.